RE: My thoughts7 Aug 2020 16:45
I know it's not the best local media but there is a piece on the evening standard:
"Small-cap spotlight
The Covid-19 bounce in a cluster of AIM-listed stocks continued apace today, as Avacta saw shares step up. The firm specialises in biotherapeutics — medicines produced from biological sources such as living organisms — and said it had entered into a collaboration with the Liverpool School of Tropical Medicine. The institution, which studies infectious diseases, will clinically validate Avacta’s saliva coronavirus test, which it is developing with life sciences firm Cytiva. The stock rose 5.7p or 4% to 139.7p."